Thrombin-Receptor Antagonist Vorapaxar in Acute Cor

New England Journal of Medicine
366, 20-33
DOI: 10.1056/nejmoa1109719

Citation Report

#	Article	IF	Citations
1	Interaction of volkensin with HeLa cells: binding, uptake, intracellular localization, degradation and exocytosis. Cellular and Molecular Life Sciences, 2004, 61, 1975-1984.	2.4	50
2	Suppression of Arterial Thrombosis Without Affecting Hemostatic Parameters With a Cell-Penetrating PAR1 Pepducin. Circulation, 2012, 126, 83-91.	1.6	75
3	Recent Development in Thrombin Receptor Antagonist as Novel Antithrombotic Agent. Open Journal of Medicinal Chemistry, 2012, 02, 112-118.	0.7	1
4	Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization. New England Journal of Medicine, 2012, 367, 1297-1309.	13.9	765
5	Defining Heart Failure End Points in ST-Segment Elevation Myocardial Infarction Trials. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 594-600.	0.9	53
6	What is the optimal antithrombotic strategy in primary percutaneous coronary intervention?. Current Opinion in Cardiology, 2012, 27, 361-367.	0.8	2
7	Thrombin-receptor antagonist increases bleeding in patients with ACS. Nature Reviews Cardiology, 2012, 9, 2-2.	6.1	0
8	Risk of Intracranial Hemorrhage With Protease-Activated Receptor-1 Antagonists. Stroke, 2012, 43, 3189-3195.	1.0	21
9	Risk of Intracranial Hemorrhage With Protease-Activated Receptor-1 Antagonists. Stroke, 2012, 43, 3158-3159.	1.0	3
10	Walking the tightrope between efficacy and bleeding. Nature Reviews Cardiology, 2012, 9, 69-71.	6.1	5
12	Rapid P2Y 12 Inhibition. Circulation: Cardiovascular Interventions, 2012, 5, 328-331.	1.4	4
13	Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease. Future Cardiology, 2012, 8, 503-511.	0.5	5
14	Preventing Platelet Thrombosis With a PAR1 Pepducin. Circulation, 2012, 126, 13-15.	1.6	11
15	Long-term antiplatelet therapy. Current Opinion in Cardiology, 2012, 27, 347-354.	0.8	1
16	Mortality in the TRACER and ATLAS ACS 2 Trials: Two More Reasons to Audit Vital Records in PLATO. Cardiology, 2012, 123, 11-14.	0.6	6
18	Challenges and Perspectives of Antiplatelet Therapy in Patients with Diabetes Mellitus and Coronary Artery Disease. Current Pharmaceutical Design, 2012, 18, 5273-5293.	0.9	19
19	Antiplatelet and Antithrombin Strategies in Acute Coronary Syndrome: State-Of-The-Art Review. Current Cardiology Reviews, 2012, 8, 239-249.	0.6	16
20	New Antithrombotic Drugs. Chest, 2012, 141, e120S-e151S.	0.4	284

#	Article	IF	Citations
21	New approaches for measurement of platelet reactivity. Blood, 2012, 119, 3378-3379.	0.6	0
22	Perioperative Management of Antiplatelet Agents in Patients Undergoing Cardiac Surgery. Journal of Cardiothoracic and Vascular Anesthesia, 2012, 26, 680-686.	0.6	7
23	A New Score for Risk Stratification of Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2012, 5, 1108-1116.	1.1	37
24	Safety and efficacy of proteaseâ€activated receptorâ€1 antagonists in patients with coronary artery disease: a metaâ€analysis of randomized clinical trials. Journal of Thrombosis and Haemostasis, 2012, 10, 2006-2015.	1.9	40
25	Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. Blood, 2012, 120, 5237-5246.	0.6	191
26	Beware of Novel Antiplatelet Therapy in Acute Coronary Syndrome Patients With Previous Stroke. Circulation, 2012, 125, 2821-2823.	1.6	24
27	Modern antiplatelet agents in coronary artery disease. Expert Review of Cardiovascular Therapy, 2012, 10, 1261-1272.	0.6	3
28	Bleeding and the Use of Antiplatelet Agents in the Management of Acute Coronary Syndromes and Atrial Fibrillation. Advances in Cardiology, 2012, 47, 125-140.	2.6	0
29	Targeting proteinase-activated receptors: therapeutic potential and challenges. Nature Reviews Drug Discovery, 2012, 11, 69-86.	21.5	272
30	Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2Â°P-TIMI 50 trial. Lancet, The, 2012, 380, 1317-1324.	6.3	202
31	Improving long-term outcome after myocardial infarction. Lancet, The, 2012, 380, 1290-1291.	6.3	0
32	Clinical review: Traumatic brain injury in patients receiving antiplatelet medication. Critical Care, 2012, 16, 228.	2.5	61
33	Biomarkers in acute coronary artery disease. Wiener Medizinische Wochenschrift, 2012, 162, 489-498.	0.5	9
34	The Year in Nonâ€“ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology, 2012, 60, 2127-2139.	1.2	13
35	Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependant on clopidogrel response. Thrombosis Research, 2012, 130, 198-202.	0.8	17
36	PAR-1 Inhibitors: A Novel Class of Antiplatelet Agents for the Treatment of Patients with Atherothrombosis. Handbook of Experimental Pharmacology, 2012, , 239-260.	0.9	11
37	Safety and efficacy of targeting platelet proteinaseâ€activated receptors in combination with existing antiâ€platelet drugs as antithrombotics in mice. British Journal of Pharmacology, 2012, 166, 2188-2197.	2.7	18
39	Oral factor Xa inhibitors for the long-term management of ACS. Nature Reviews Cardiology, 2012, 9, 392-401.	6.1	5

#	Article	IF	Citations
40	The Evolution of Antiplatelet Therapy in the Treatment of Acute Coronary Syndromes. Drugs, 2012, 72, 2087-2116.	4.9	106
41	New Directions in Antiplatelet Therapy. Circulation: Cardiovascular Interventions, 2012, 5, 433-445.	1.4	61
43	PAR-1 inhibitor antiplatelet agents: Performance below par?. Indian Heart Journal, 2012, 64, 594-597.	0.2	0
44	Representation of Older Adults in the Late-Breaking Clinical Trials American Heart Association 2011 Scientific Sessions. Journal of the American College of Cardiology, 2012, 60, 869-871.	1.2	11
45	The Year in Atherothrombosis. Journal of the American College of Cardiology, 2012, 60, 932-942.	1.2	14
46	The Illusion of â€œOptimalâ€•Platelet Inhibition. JACC: Cardiovascular Interventions, 2012, 5, 278-280.	1.1	8
47	P2Y12 platelet reactivity after thrombolytic therapy for ST-segment elevation myocardial infarction. Thrombosis Research, 2012, 130, e31-e36.	0.8	19
48	Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 889-900.	1.5	4
49	Use of New-Generation Oral Anticoagulant Agents in Patients Receiving Antiplatelet Therapy After an Acute Coronary Syndrome. Archives of Internal Medicine, 2012, 172, 1537.	4.3	67
50	Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting. New England Journal of Medicine, 2012, 367, 2100-2109.	13.9	788
51	Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives. Expert Review of Clinical Pharmacology, 2012, 5, 319-336.	1.3	44
52	Mechanisms of Platelet Activation and Integrin Î±IIÎ²3. Korean Circulation Journal, 2012, 42, 295.	0.7	46
54	Platelets in the pathogenesis of vascular disease and their role as a therapeutic target. , 2011, , 201-226.		2
55	Vorapaxar expands antiplatelet options. Hamostaseologie, 2012, 32, 221-227.	0.9	8
56	Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and a History of Stroke or Transient Ischemic Attack. Circulation, 2012, 125, 2914-2921.	1.6	112
57	Vorapaxar in the Secondary Prevention of Atherothrombotic Events. New England Journal of Medicine, 2012, 366, 1404-1413.	13.9	841
58	Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin. European Journal of Clinical Pharmacology, 2012, 68, 1509-1516.	0.8	9
59	Discovery of 1,3-Diaminobenzenes as Selective Inhibitors of Platelet Activation at the PAR1 Receptor. ACS Medicinal Chemistry Letters, 2012, 3, 232-237.	1.3	39

#	Article	IF	Citations
61	Antithrombotic therapy in patients with acute coronary syndrome and diabetes mellitus. Herz, 2012, 37, 264-272.	0.4	2
62	Differentiating ischemic from non-ischemic chest pain using white blood cell-surface inflammatory and coagulation markers. Journal of Thrombosis and Thrombolysis, 2012, 34, 235-243.	1.0	5
63	Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program. Journal of Thrombosis and Thrombolysis, 2012, 34, 36-43.	1.0	16
64	Platelet Function and Inhibition in Ischemic Heart Disease. Current Cardiology Reports, 2012, 14, 457-467.	1.3	15
65	Management of acute coronary syndrome: achievements and goals still to pursue. Novel developments in diagnosis and treatment. Journal of Internal Medicine, 2012, 271, 521-536.	2.7	18
66	The impact of blood coagulability on atherosclerosis and cardiovascular disease. Journal of Thrombosis and Haemostasis, 2012, 10, 1207-1216.	1.9	95
67	Improving Longâ€Term ACS Management: Is There a Role for the New Antiplatelets?. Journal of Interventional Cardiology, 2012, 25, 425-432.	0.5	4
68	Novel antithrombotic agents for atrial fibrillation. , 2012, 134, 345-354.		3
69	Harnessing the Platelet Signaling Network to Produce an Optimal Hemostatic Response. Hematology/Oncology Clinics of North America, 2013, 27, 381-409.	0.9	26
70	Emerging antithrombotic drugs for acute coronary syndrome. Expert Opinion on Emerging Drugs, 2013, 18, 307-318.	1.0	1
71	Nonbenzamidine acylsulfonamide tissue factorâ€“factor VIIa inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5244-5248.	1.0	17
72	Platelet Biology and Receptor Pathways. Journal of Cardiovascular Translational Research, 2013, 6, 299-309.	1.1	64
73	Platelet Function Profiles in Patients with Diabetes Mellitus. Journal of Cardiovascular Translational Research, 2013, 6, 329-345.	1.1	46
74	Oral Antiplatelet Therapy in Acute Coronary Syndromes: Recent Developments. Cardiology and Therapy, 2013, 2, 47-56.	1.1	7
75	Thrombin Receptor Antagonism in Antiplatelet Therapy. Cardiology and Therapy, 2013, 2, 57-68.	1.1	10
76	The Year in Interventional Cardiology. Journal of the American College of Cardiology, 2013, 61, 1637-1652.	1.2	1
77	Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation. Translational Research, 2013, 161, 421-429.	2.2	35
78	Basics of Antithrombotic Therapy for Cardiovascular Disease. Interventional Cardiology Clinics, 2013, 2, 499-513.	0.2	1

#	Article	IF	Citations
79	Investigational anticoagulants for hematological conditions: a new generation of therapies. Expert Opinion on Investigational Drugs, 2013, 22, 1281-1294.	1.9	8
80	Rescuing clinical trials in the United States and beyond: A call for action. American Heart Journal, 2013, 165, 837-847.	1.2	45
81	Lost in follow-up rates in TRACER, ATLAS ACS 2, TRITON and TRA 2P trials: Challenging PLATO mortality rates. International Journal of Cardiology, 2013, 164, 255-258.	0.8	10
82	Novel oral anticoagulants in acute coronary syndrome. International Journal of Cardiology, 2013, 167, 2449-2455.	0.8	31
83	Updates in Antiplatelet Agents Used in Cardiovascular Diseases. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 514-524.	1.0	23
84	Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacyâ€. European Heart Journal, 2013, 34, 1621-1629.	1.0	9
86	Pathologies at the nexus of blood coagulation and inflammation: thrombin in hemostasis, cancer, and beyond. Journal of Molecular Medicine, 2013, 91, 1257-1271.	1.7	97
87	Dual Antiplatelet Therapy Dilemmas: Duration and Choice of Antiplatelets in Acute Coronary Syndromes. Current Cardiology Reports, 2013, 15, 405.	1.3	5
88	Pharmacology of Antiplatelet Agents. Current Atherosclerosis Reports, 2013, 15, 371.	2.0	23
89	Pretreatment with Prasugrel in Nonâ€“ST-Segment Elevation Acute Coronary Syndromes. New England Journal of Medicine, 2013, 369, 999-1010.	13.9	539
90	Platelet Antiaggregants in Stroke Prevention. Neurologic Clinics, 2013, 31, 633-657.	0.8	7
91	Preserved thrombinâ€inducible platelet activation in thienopyridineâ€treated patients. European Journal of Clinical Investigation, 2013, 43, 689-697.	1.7	15
92	Inflammation and coagulation in atherosclerosis. Hamostaseologie, 2013, 33, 269-282.	0.9	36
93	Protease-Activated Receptor (PAR) 1 and PAR4 Differentially Regulate Factor V Expression from Human Platelets. Molecular Pharmacology, 2013, 83, 781-792.	1.0	55
94	Coagulation and coagulation signalling in fibrosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1018-1027.	1.8	91
95	New Fundamentals in Hemostasis. Physiological Reviews, 2013, 93, 327-358.	13.1	817
96	Prasugrel Reduces Agonistsâ€² Inducible Platelet Activation and Leukocyteâ€“Platelet Interaction more efficiently than Clopidogrel. Cardiovascular Therapeutics, 2013, 31, e40-5.	1.1	27
97	2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2013, 61, e78-e140.	1.2	2,612

#	Article	IF	Citations
98	Low-Dose Anticoagulation for Secondary Prevention in Acute Coronary Syndrome. American Journal of Cardiology, 2013, 111, 618-626.	0.7	12
99	PAR-1 antagonists: current state of evidence. Journal of Thrombosis and Thrombolysis, 2013, 35, 1-9.	1.0	15
100	Dichotomous effects of exposure to bivalirudin in patients undergoing percutaneous coronary intervention on protease-activated receptor-mediated platelet activation. Journal of Thrombosis and Thrombolysis, 2013, 35, 209-222.	1.0	4
101	Cardiac Troponin After Percutaneous CoronaryÂIntervention and 1-YearÂMortality inÂNonâ€“ST-Segment Elevation Acute Coronary SyndromeÂUsingÂSystematic Evaluation ofÂBiomarkerÂTrends. Journal of the American College of Cardiology, 2013, 62, 242-251.	1.2	39
103	Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges. International Journal of Cardiology, 2013, 167, 1772-1782.	0.8	67
104	The nuances of new antiplatelet drugs in acute coronary syndrome. Journal of Indian College of Cardiology, 2013, 3, 16-23.	0.1	1
105	Highly functionalized 2-oxopiperazine-based peptidomimetics: An approach to PAR1 antagonists. European Journal of Medicinal Chemistry, 2013, 70, 199-224.	2.6	7
106	Residual platelet activation through protease-activated receptors (PAR)-1 and â€4 in patients on P2Y12 inhibitors. International Journal of Cardiology, 2013, 168, 403-406.	0.8	28
107	Between a Rock and a Hard Place: Weighing Thrombotic Risk Against Bleeding Complications. American Journal of Cardiology, 2013, 111, 1375.	0.7	0
108	Benefits and risks of long-term duration of dual antiplatelet therapy after drug-eluting stenting: A meta-analysis of randomized trials. International Journal of Cardiology, 2013, 168, 2579-2587.	0.8	39
109	Update on Ischemic Heart Disease and Critical Care Cardiology. Revista Espanola De Cardiologia (English Ed), 2013, 66, 198-204.	0.4	5
110	Patient- and Trial-Specific Barriers to Participation in Cardiovascular Randomized Clinical Trials. Journal of the American College of Cardiology, 2013, 61, 762-769.	1.2	68
112	Incorporation of bleeding as an element of the composite end point in clinical trials of antithrombotic therapies in patients with nonâ€“ST-segment elevation acute coronary syndrome: Validity, pitfalls, and future approaches. American Heart Journal, 2013, 165, 644-654.e1.	1.2	8
113	Influence of platelet reactivity and inflammation on peri-procedural myonecrosis in East Asian patients undergoing elective percutaneous coronary intervention. International Journal of Cardiology, 2013, 168, 427-435.	0.8	3
115	Risk Estimation Scores Do Not Mean Everything: What About Plaque Burden and Prognosis?. American Journal of Cardiology, 2013, 111, 1374-1375.	0.7	0
116	Protease-Activated Receptors. , 2013, , 249-259.		7
117	Pharmacodynamic interplay of the P2Y1, P2Y12, and TxA2 pathways in platelets: The potential of triple antiplatelet therapy with P2Y1 receptor antagonism. Thrombosis Research, 2013, 131, e64-e70.	0.8	6
118	Key Advances in Clinical Cardiology. Advances in Therapy, 2013, 30, 369-386.	1.3	4

#	Article	IF	Citations
119	General mechanisms of coagulation and targets of anticoagulants (Section I). Thrombosis and Haemostasis, 2013, 109, 569-579.	1.8	165
120	Reduction of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Rivaroxaban in ATLAS-ACS 2 TIMI 51. Journal of the American College of Cardiology, 2013, 62, 286-290.	1.2	88
121	Novel Anti-platelet Agents: Focus on Thrombin Receptor Antagonists. Journal of Cardiovascular Translational Research, 2013, 6, 415-424.	1.1	22
122	Pharmacotherapy for the reduction of stent thrombosis. Expert Review of Cardiovascular Therapy, 2013, 11, 567-576.	0.6	1
123	Novel anti-thrombotic therapy in acute coronary syndromes. Cor Et Vasa, 2013, 55, e117-e125.	0.1	0
124	The ATLAS ACS 2â€“TIMI 51 Trial and the Burden of Missing Data. Journal of the American College of Cardiology, 2013, 62, 777-781.	1.2	31
125	Optimal Choice of Coronary Revascularization and Stent Type in Diabetic Patients with Coronary Artery Disease. Cardiology and Therapy, 2013, 2, 69-84.	1.1	1
126	Response to antiplatelet therapy is independent of endogenous thrombin generation potential. Thrombosis Research, 2013, 132, e24-e30.	0.8	11
127	Antiplatelet and Anticoagulant Therapy for Atherothrombotic Disease: The Role of Current and Emerging Agents. American Journal of Cardiovascular Drugs, 2013, 13, 233-250.	1.0	36
128	Antiplatelet Agents: Current and Novel. , 2013, , 1-44.		1
129	Acute Coronary Syndromes: Advances in Antithrombotics. Current Atherosclerosis Reports, 2013, 15, 318.	2.0	3
130	Antiplatelet therapy: new pharmacological agents and changing paradigms. Journal of Thrombosis and Haemostasis, 2013, 11, 316-329.	1.9	61
131	Protease-activated Receptor 1 (PAR1) and PAR4 Heterodimers Are Required for PAR1-enhanced Cleavage of PAR4 by Î±-Thrombin. Journal of Biological Chemistry, 2013, 288, 32553-32562.	1.6	67
132	Percutaneous biventricular cardiac assist device in cardiogenic shock. European Heart Journal, 2013, 34, 1620-1620.	1.0	12
133	Any room left for new antiplatelet agents in acute coronary syndrome?. European Heart Journal, 2013, 34, 1699-1701.	1.0	1
134	Percutaneous coronary intervention in diabetic patients: should choice of stents be influenced?. Expert Review of Cardiovascular Therapy, 2013, 11, 541-553.	0.6	8
135	Efficacy and Safety of Vorapaxar in Patients With Prior Ischemic Stroke. Stroke, 2013, 44, 691-698.	1.0	89
136	Antiplatelet Drug Use in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes. Postgraduate Medicine, 2013, 125, 51-58.	0.9	2

#	Article	IF	Citations
137	A History of Stroke/Transient Ischemic Attack Indicates High Risks of Cardiovascular Event and Hemorrhagic Stroke in Patients With Coronary Artery Disease. Circulation, 2013, 127, 730-738.	1.6	74
138	Long-Term Outcomes After Invasive Management for Older Patients With Nonâ€"ST-Segment Elevation Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 323-332.	0.9	15
139	Targeting Platelet Thrombin Receptor Signaling to Prevent Thrombosis. Pharmaceuticals, 2013, 6, 915-928.	1.7	10
140	Historical Lessons in Translational Medicine. Circulation Research, 2013, 112, 174-194.	2.0	38
141	Diagnosis and Management of Ischemic Heart Disease. Seminars in Thrombosis and Hemostasis, 2013, 39, 202-213.	1.5	59
142	2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. Circulation, 2013, 127, e362-425.	1.6	2,639
143	Elderly Patients With Acute Coronary Syndromes Managed Without Revascularization. Circulation, 2013, 128, 823-833.	1.6	130
144	Plasmin Activation of Glial Cells through Protease-Activated Receptor 1. Pathology Research International, 2013, 2013, 1-8.	1.4	6
145	Combined antiplatelet and novel oral anticoagulant therapy after acute coronary syndrome: is three a crowd?. European Heart Journal, 2013, 34, 1618-1620.	1.0	11
146	Pharmacologic Options for Treatment of Ischemic Disease. , 2013, , 83-130.		4
147	The Influence of Multipleâ€Dose Vorapaxar, an Oral PARâ€1 Receptor Antagonist, on the Singleâ€Dose Pharmacokinetics and Pharmacodynamics of Digoxin. Clinical Pharmacology in Drug Development, 2013, 2, 90-98.	0.8	4
148	Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review. European Heart Journal, 2013, 34, 894-902.	1.0	21
149	Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA{middle dot}CER) trial. European Heart Journal, 2013, 34, 1723-1731.	1.0	36
150	The Effect of Multiple Doses of Ketoconazole or Rifampin on the Singleâ€•and Multipleâ€Dose Pharmacokinetics of Vorapaxar. Journal of Clinical Pharmacology, 2013, 53, 540-549.	1.0	19
152	Efficacy of Antiplatelet Treatment in Stroke Prevention: Past, Present, and Future. Drug Development Research, 2013, 74, 428-439.	1.4	0
153	Noncanonical Matrix Metalloprotease-1-Protease-activated Receptor-1 Signaling Triggers Vascular Smooth Muscle Cell Dedifferentiation and Arterial Stenosis. Journal of Biological Chemistry, 2013, 288, 23105-23115.	1.6	41
154	Ticagrelor for acute coronary syndromes. Expert Review of Cardiovascular Therapy, 2013, 11, 1473-1484.	0.6	3
155	Novel Anti-platelet Agents for the Treatment of Stable Angina Pectoris. Current Pharmaceutical Design, 2013, 19, 1581-1586.	0.9	1

#	Article	IF	Citations
156	Platelet Function in Ischemic Heart Disease. Journal of Cardiovascular Pharmacology, 2013, 61, 166-174.	0.8	14
157	High on-treatment platelet reactivity - why should we be concerned?. Thrombosis and Haemostasis, 2013, 109, 789-791.	1.8	7
158	Novel antiplatelet drugs in clinical development. Thrombosis and Haemostasis, 2013, 110, 868-875.	1.8	22
159	Antiplatelet Therapy in the Prevention of Coronary Syndromes: Mode of Action, Benefits, Drawbacks. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2013, 11, 49-57.	0.4	2
160	Hemostatic Aspects of Cardiovascular Medicine. , 2013, , 342-394.		0
161	Vorapaxar. Italian Journal of Medicine, 0, , 88-95.	0.2	0
162	Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar. Vascular Health and Risk Management, 2014, 10, 177.	1.0	13
163	Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. Thrombosis and Haemostasis, 2014, 112, 883-891.	1.8	27
164	Efficacy versus safety: the dilemma of using novel platelet inhibitors for the treatment of patients with ischemic stroke and coronary artery disease. Therapeutics and Clinical Risk Management, 2014, 10, 321.	0.9	5
165	Subgroup analyses with special reference to the effect of antiplatelet agents in acute coronary syndromes. Thrombosis and Haemostasis, 2014, 112, 16-25.	1.8	3
166	Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity. Thrombosis and Haemostasis, 2014, 112, 1198-1208.	1.8	6
168	Pharmacology: A new bleeding issue. British Dental Journal, 2014, 217, 54-55.	0.3	1
169	Future prospects for contact factors as therapeutic targets. Hematology American Society of Hematology Education Program, 2014, 2014, 52-59.	0.9	19
170	Differential Signaling by Protease-Activated Receptors: Implications for Therapeutic Targeting. International Journal of Molecular Sciences, 2014, 15, 6169-6183.	1.8	34
171	Platelets and their chemokines in atherosclerosisÃ¢â‚¬â€clinical applications. Frontiers in Physiology, 2014, 5, 294.	1.3	104
173	Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. European Heart Journal, 2014, 35, 209-215.	1.0	224
175	Effect of Prasugrel Pre-Treatment Strategy in Patients Undergoing Percutaneous Coronary Intervention for NSTEMI. Journal of the American College of Cardiology, 2014, 64, 2563-2571.	1.2	64
176	Rivaroxaban in acute coronary syndromes â€“ is it prime time?. Expert Review of Cardiovascular Therapy, 2014, 12, 649-658.	0.6	1

#	Article	IF	Citations
178	Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives. Expert Review of Cardiovascular Therapy, 2014, 12, 963-976.	0.6	0
179	Contemporary antiplatelet therapy in patients undergoing percutaneous coronary intervention. Expert Review of Cardiovascular Therapy, 2014, 12, 463-474.	0.6	2
180	New Antithrombotics for Secondary Prevention of Acute Coronary Syndrome. Clinical Cardiology, 2014, 37, 178-187.	0.7	20
181	Vorapaxar, Combination Antiplatelet Therapy, and Strokeâ^—. Journal of the American College of Cardiology, 2014, 64, 2327-2329.	1.2	3
182	Vorapaxar with or without clopidogrel after nonâ€“ST-segment elevation acute coronary syndromes: Results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial. American Heart Journal, 2014, 168, 869-877.e1.	1.2	21
183	Effect of the thrombin receptor antagonist (PARâ€1) vorapaxar on QT/QTc interval in healthy volunteers: A randomized, placeboâ€•and positiveâ€controlled, parallel group trial. Clinical Pharmacology in Drug Development, 2014, 3, 18-24.	0.8	8
184	Pretreatment with P2Y ₁₂ Inhibitors in Nonâ€“ST-Segmentâ€“Elevation Acute Coronary Syndrome: An Outdated and Harmful Strategy. Circulation, 2014, 130, 1904-1914.	1.6	36
186	Role of Clinical Pharmacology in the Development of Antiplatelet Drugs. Clinical Therapeutics, 2014, 36, 2096-2111.	1.1	8
187	Effect of preoperative P2Y12 and thrombin platelet receptor inhibition on bleeding after cardiac surgery. British Journal of Anaesthesia, 2014, 113, 970-976.	1.5	91
188	Targeting the anionic region of human proteaseâ€activated receptorÂ4 inhibits platelet aggregation and thrombosis without interfering with hemostasis. Journal of Thrombosis and Haemostasis, 2014, 12, 1331-1341.	1.9	29
189	Recent advances in antithrombotic treatment for acute coronary syndromes. Expert Review of Clinical Pharmacology, 2014, 7, 507-521.	1.3	5
190	Targeting Therapy to the Fibrin-Mediated Pathophysiology of Acute Coronary Syndrome. Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 516-523.	0.7	4
191	Race Differences in Platelet Reactivity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2524-2526.	1.1	6
192	The potential role of anticoagulant therapy for the secondary prevention of ischemic events post-acute coronary syndrome. Current Medical Research and Opinion, 2014, 30, 2151-2167.	0.9	2
193	Platelet function inhibitors and platelet function testing in neurointerventional procedures: TableÂ1. Journal of NeuroInterventional Surgery, 2014, 6, 567-577.	2.0	37
194	Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER. Journal of the American Heart Association, 2014, 3, .	1.6	9
195	Antiplatelet Treatment in the Secondary Prevention of Coronary and Cerebrovascular Disease. Angiology, 2014, 65, 473-490.	0.8	3
196	Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: Differences between peripheral and coronary angioplasty. Atherosclerosis, 2014, 232, 119-124.	0.4	31

#	Article	IF	Citations
197	Independent data monitoring committees: Preparing a path for the future. American Heart Journal, 2014, 168, 135-141.e1.	1.2	16
198	Reversal of Trauma-Induced Amnesia in Mice by a Thrombin Receptor Antagonist. Journal of Molecular Neuroscience, 2014, 53, 87-95.	1.1	31
199	Antiplatelet Treatment for Prevention of Cerebrovascular Events in Patients With Vascular Diseases. Stroke, 2014, 45, 492-503.	1.0	63
200	Rivaroxaban: A Review of Its Use in Acute Coronary Syndromes. Drugs, 2014, 74, 451-464.	4.9	9
201	Lessons Learned from Negative Clinical Trials Evaluating Antithrombotic Therapy for Ischemic Heart Disease. Journal of Cardiovascular Translational Research, 2014, 7, 112-125.	1.1	0
202	Association of Thrombin Generation Potential with Platelet PAR-1 Regulation and P-Selectin Expression in Patients on Dual Antiplatelet Therapy. Journal of Cardiovascular Translational Research, 2014, 7, 126-132.	1.1	5
203	Joint British Societiesâ€™ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart, 2014, 100, ii1-ii67.	1.2	441
204	Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions. Thrombosis Research, 2014, 133, 66-72.	0.8	26
205	Pharmacological Treatment of Acute Coronary Syndromes. , 2014, , .		2
206	Targeting platelet receptor function in thrombus formation: The risk of bleeding. Blood Reviews, 2014, 28, 9-21.	2.8	43
207	Comparison of Clinical Trial Outcome Patterns in Patients Following Acute Coronary Syndromes and in Patients With Chronic Stable Atherosclerosis. Clinical Cardiology, 2014, 37, 337-342.	0.7	8
210	Role of protease-activated receptors for the innate immune response of the heart. Trends in Cardiovascular Medicine, 2014, 24, 249-255.	2.3	14
211	The â€œDualâ€Pathwayâ€•Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2â€•TIMI 51 Trial. Cardiovascular Therapeutics, 2014, 32, 224-232.	1.1	10
212	Himbacine-Derived Thrombin Receptor Antagonists: C7-Aminomethyl and C9a-Hydroxy Analogues of Vorapaxar. ACS Medicinal Chemistry Letters, 2014, 5, 183-187.	1.3	2
213	Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: Insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). American Heart Journal, 2014, 168, 588-596.	1.2	44
214	Expression of Protease Activated Receptor-1 in Chronic Periodontitis. Journal of Periodontology, 2014, 85, 1763-1769.	1.7	12
215	Syndrome coronaire aigu : peut-on et comment amÃ©liorer le pronostic ?. Archives of Cardiovascular Diseases Supplements, 2014, 6, 102-109.	0.0	0
216	Vorapaxar: First Global Approval. Drugs, 2014, 74, 1153-1163.	4.9	22

#	Article	IF	Citations
217	Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 246-256.	0.4	13
218	Usefulness and Safety of Vorapaxar in Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (from the TRACER Trial). American Journal of Cardiology, 2014, 114, 665-673.	0.7	17
220	DurÃ©e de la bithÃ©rapie antiplaquettaire aprÃ¨s mise en place dâ€™un stent actif. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2014, 2014, 15-18.	0.0	0
221	Update on Ischemic Heart Disease and Critical Care Cardiology. Revista Espanola De Cardiologia (English Ed), 2014, 67, 120-126.	0.4	3
222	PAR-1 antagonist vorapaxar favorably improves global thrombotic status in patients with coronary disease. Journal of Thrombosis and Thrombolysis, 2014, 38, 423-429.	1.0	18
223	Secondary Prevention Strategies for Acute Coronary Syndrome. Revista Espanola De Cardiologia (English Ed), 2014, 67, 844-848.	0.4	5
224	Antiplatelet and anticoagulation agents in acute coronary syndromes: What is the current status and what does the future hold?. American Heart Journal, 2014, 168, 611-621.	1.2	34
225	Estrategias de prevenciÃ³n secundaria del sÃndrome coronario agudo. Revista Espanola De Cardiologia, 2014, 67, 844-848.	0.6	15
227	Vorapaxar in Patients Undergoing Coronary Artery Bypass Grafting. Journal of the American College of Cardiology, 2014, 63, 1058-1060.	1.2	1
228	Implications of prior myocardial infarction for patients presenting with an acute myocardial infarction. American Heart Journal, 2014, 167, 840-845.	1.2	16
229	Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery. Journal of the American College of Cardiology, 2014, 63, 1048-1057.	1.2	40
231	Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial). American Journal of Cardiology, 2014, 113, 936-944.	0.7	17
232	Antiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes. Circulation Research, 2014, 114, 1929-1943.	2.0	79
233	Pharmacokinetic evaluation of prasugrel for the treatment of myocardial infarction. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 609-620.	1.5	3
234	Himbacine-Derived Thrombin Receptor Antagonists: C₇-Spirocyclic Analogues of Vorapaxar. ACS Medicinal Chemistry Letters, 2014, 5, 561-565.	1.3	12
235	Functional role of protease activated receptors in vascular biology. Vascular Pharmacology, 2014, 62, 72-81.	1.0	81
237	Antiplatelet Therapy in Patients With Diabetes Mellitus and Acute Coronary Syndrome. Circulation Journal, 2014, 78, 33-41.	0.7	22
238	Antithrombotic Drugs and Their Complications. , 2014, , 1613-1627.		2

#	Article	IF	Citations
239	Antiplatelet drugs: which targets for which treatments?. Journal of Thrombosis and Haemostasis, 2015, 13, S313-S322.	1.9	47
240	Platelets: Small in Size But Essential in the Regulation of Vascular Homeostasisã€€â€“ Translation From Basic Science to Clinical Medicine â€“. Circulation Journal, 2015, 79, 1871-1881.	0.7	26
241	Ticagrelor vs. Clopidogrel in Japanese, Korean and Taiwanese Patients With Acute Coronary Syndromeã€€â€“ Randomized, Double-Blind, Phase III PHILO Study â€“. Circulation Journal, 2015, 79, 2452-2460.	0.7	218
242	Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar. Blood, 2015, 125, 1976-1985.	0.6	71
244	2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. Revista Espanola De Cardiologia (English Ed), 2015, 68, 1125.	0.4	57
245	Platelet function recovery following exposure to triple anti-platelet inhibitors using an in vitro transfusion model. Thrombosis Research, 2015, 136, 1216-1223.	0.8	9
246	Factor XI and contact activation as targets for antithrombotic therapy. Journal of Thrombosis and Haemostasis, 2015, 13, 1383-1395.	1.9	110
247	Vorapaxar. Cardiology in Review, 2015, 23, 261-267.	0.6	8
248	Exploration of efficacy and bleeding with combined phosphoinositide 3â€kinase Î² inhibition and aspirin in man. Journal of Thrombosis and Haemostasis, 2015, 13, 1494-1502.	1.9	39
249	Efficacy and Safety of Vorapaxar in Nonâ€“STâ€Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery. Journal of the American Heart Association, 2015, 4, .	1.6	8
250	Lost to Follow-up and Withdrawal of Consent in Contemporary Global Cardiovascular Randomized Clinical Trials. Critical Pathways in Cardiology, 2015, 14, 150-153.	0.2	1
251	Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges. Thrombosis and Haemostasis, 2015, 114, 1104-1112.	1.8	40
252	Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar. Drug Design, Development and Therapy, 2015, 9, 3801.	2.0	2
253	Current Antiplatelet Treatment Strategy in Patients with Diabetes Mellitus. Diabetes and Metabolism Journal, 2015, 39, 95.	1.8	40
254	Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis. Therapeutics and Clinical Risk Management, 2015, 11, 1133.	0.9	6
255	Cancer after intense and prolonged antiplatelet therapies â€“ fact or fiction?. Thrombosis and Haemostasis, 2015, 114, 1100-1103.	1.8	4
256	P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use. Therapeutic Advances in Chronic Disease, 2015, 6, 204-218.	1.1	4
257	Magnitude of Troponin Elevation and Long-Term Clinical Outcomes in Acute Coronary Syndrome Patients Treated With and Without Revascularization. Circulation: Cardiovascular Interventions, 2015, 8, e002314.	1.4	22

#	Article	IF	Citations
258	Selection of a Suitable Patient Population for New Antiplatelet Therapy From the Large Clinical Trial Database of the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Eventsâ€“Thrombolysis in Myocardial Infarction 50 (TRA-2Pâ€“TIMI50) Trial. Circulation, 2015, 131, 1041-1043.	1.6	9
259	Risks and Benefits of Triple Oral Anti-Thrombotic Therapies After Acute Coronary Syndromes and Percutaneous Coronary Intervention. Drug Safety, 2015, 38, 481-491.	1.4	6
260	Pharmacological Treatment and Current Management of Peripheral Artery Disease. Circulation Research, 2015, 116, 1579-1598.	2.0	87
261	The future of P2Y₁₂ receptor antagonists. Platelets, 2015, 26, 392-398.	1.1	12
262	Rare platelet <scp>GPCR</scp> variants: what can we learn?. British Journal of Pharmacology, 2015, 172, 3242-3253.	2.7	10
263	Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States. Journal of the American Heart Association, 2015, 4, e001505.	1.6	62
264	Infusion of Reconstituted Highâ€Ðensity Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial. Journal of the American Heart Association, 2015, 4, e002171.	1.6	89
265	Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development. Future Cardiology, 2015, 11, 547-564.	0.5	17
267	Treating coronary artery disease in patients with a history of cerebrovascular disease. Archives of Cardiovascular Diseases, 2015, 108, 606-611.	0.7	5
268	Thrombin-induced reactive oxygen species generation in platelets: A novel role for protease-activated receptor 4 and GPIbÎ±. Redox Biology, 2015, 6, 640-647.	3.9	59
269	PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact. Platelets, 2015, 26, 236-242.	1.1	21
270	New Approaches to Inhibiting Platelets and Coagulation. Annual Review of Pharmacology and Toxicology, 2015, 55, 373-397.	4.2	44
271	Contemporary antithrombotic strategies in patients with acute coronary syndromes managed without revascularization: insights from the EYESHOT study. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 168-178.	1.4	22
272	Vorapaxar in Atherosclerotic Disease Management. Annals of Pharmacotherapy, 2015, 49, 599-606.	0.9	3
273	Dual antiplatelet response during PCI: VerifyNow P2Y12 predicts myocardial necrosis and thromboxane B2 generation confirms wide variation in aspirin response. Thrombosis Research, 2015, 135, 1140-1146.	0.8	3
274	Current antiplatelet agents: place in therapy and role of genetic testing. Journal of Thrombosis and Thrombolysis, 2015, 39, 328-336.	1.0	2
275	Pretreatment With Antiplatelet Drugs in Invasively Managed Patients With Coronary Artery Disease in the Contemporary Era. Circulation: Cardiovascular Interventions, 2015, 8, e002301.	1.4	58
276	In vitro pharmacological characterization of vorapaxar, a novel platelet thrombin receptor antagonist. European Journal of Pharmacology, 2015, 762, 221-228.	1.7	11

#	Article	IF	Citations
277	Redesigning TRACER trial after TRITON. International Journal of Cardiology, 2015, 197, 44-47.	0.8	6
278	Risk and benefit of direct oral anticoagulants or PAR-1 antagonists in addition to antiplatelet therapy in patients with acute coronary syndrome. Thrombosis Research, 2015, 136, 243-249.	0.8	2
279	Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome. Heart, 2015, 101, 1475-1484.	1.2	13
280	Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. European Heart Journal, 2015, 36, ehv304.	1.0	175
281	Antiplatelet Drugs in the Management of Cardiovascular Indications. , 2015, , 953-973.		0
282	Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndromes (from the) Tj ETQq1 1 0.784314 rgBT /Over	0.7843141	12
283	Balancing the Risks and Benefits of Longâ€Term Antiplatelet Therapies for Cardiovascular Disease: Clinical, Research, and Regulatory Implications. Journal of the American Heart Association, 2015, 4, e001897.	1.6	1
284	Novel Antiplatelet Agents in Cardiovascular Medicine. Current Treatment Options in Cardiovascular Medicine, 2015, 17, 383.	0.4	3
285	Protease-activated receptor-1 antagonists in long-term antiplatelet therapy. Current state of evidence and future perspectives. International Journal of Cardiology, 2015, 185, 9-18.	0.8	22
286	Dual Pathway Therapy for Secondary Prevention Following Acute Coronary Syndrome. Current Cardiovascular Risk Reports, 2015, 9, 1.	0.8	0
287	Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist. European Journal of Pharmacology, 2015, 758, 107-114.	1.7	14
288	Vorapaxar: A Review of Its Use in the Long-Term Secondary Prevention of Atherothrombotic Events. Drugs, 2015, 75, 797-808.	4.9	16
289	Secondary Prevention of Cardiovascular Disease With Vorapaxar. JAMA Internal Medicine, 2015, 175, 9.	2.6	10
290	Discovery of Novel P1 Groups for Coagulation Factor VIIa Inhibition Using Fragment-Based Screening. Journal of Medicinal Chemistry, 2015, 58, 2799-2808.	2.9	19
291	Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet, The, 2015, 386, 292-302.	6.3	59
292	Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Nonâ€“ST-Segment Elevation Acute Coronary Syndrome Patients. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 357-367.	0.9	30
293	Investigational new drugs for the treatment of acute coronary syndrome. Expert Opinion on Investigational Drugs, 2015, 24, 1557-1570.	1.9	3
295	Antithrombotic therapy for stable coronary artery disease: the difficult quest for the holy balance. European Heart Journal, 2015, 37, ehv471.	1.0	1

#	Article	IF	Citations
296	Coagulationâ€driven platelet activation reduces cholestatic liver injury and fibrosis in mice. Journal of Thrombosis and Haemostasis, 2015, 13, 57-71.	1.9	45
297	Review of vorapaxar for the prevention of atherothrombotic events. Expert Opinion on Pharmacotherapy, 2015, 16, 2509-2522.	0.9	12
298	Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. American Journal of Health-System Pharmacy, 2015, 72, 1615-1622.	0.5	9
299	Antiplatelet therapy in acute coronary syndromes. Expert Opinion on Pharmacotherapy, 2015, 16, 2133-2147.	0.9	30
300	Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike. Progress in Cardiovascular Diseases, 2015, 58, 267-277.	1.6	22
301	Efficacy and Safety of Thrombin-Receptor Antagonist (Atopaxar and Vorapaxar) in Patients with Acute Coronary Syndrome or Coronary Artery Diseaseâ€"A Meta-Analysis of Randomized Controlled Trials. Value in Health Regional Issues, 2015, 6, 22-32.	0.5	4
302	Cardiovascular Effects of Exposure to Cigarette Smoke and Electronic Cigarettes. Journal of the American College of Cardiology, 2015, 66, 1378-1391.	1.2	164
303	Vorapaxar for secondary stroke prevention: perspectives and obstacles. Expert Review of Neurotherapeutics, 2015, 15, 1377-1382.	1.4	3
304	The FDA report on vorapaxar in the elderly: A convoluted dilemma. International Journal of Cardiology, 2015, 201, 601-603.	0.8	4
305	Metaâ€Analysis of Intracranial Hemorrhage in Acute Coronary Syndromes: Incidence, Predictors, and Clinical Outcomes. Journal of the American Heart Association, 2015, 4, e001512.	1.6	19
306	Vorapaxar in the secondary prevention of atherothrombosis. Expert Review of Cardiovascular Therapy, 2015, 13, 1293-1305.	0.6	13
307	Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner?. Expert Review of Cardiovascular Therapy, 2015, 13, 1333-1344.	0.6	7
308	Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent. Blood Reviews, 2015, 29, 179-189.	2.8	43
309	Novel antiplatelet agents in acute coronary syndrome. Nature Reviews Cardiology, 2015, 12, 30-47.	6.1	299
310	Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar. Vascular Health and Risk Management, 2016, 12, 263.	1.0	8
311	Optimal medical therapy for secondary prevention after an acute coronary syndrome: 18-month follow-up results at a tertiary teaching hospital in South Korea. Therapeutics and Clinical Risk Management, 2016, 12, 167.	0.9	7
312	Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation. Thrombosis and Haemostasis, 2016, 115, 905-910.	1.8	5
313	The Role of Genetics in Acute Coronary Syndrome. , 2016, , 25-55.		0

#	Article	IF	Citations
314	When is the Best Time for the Second Antiplatelet Agent in Non-St Elevation Acute Coronary Syndrome?. Arquivos Brasileiros De Cardiologia, 2016, 106, 236-46.	0.3	4
315	Efficacy and safety of vorapaxar for the prevention of adverse cardiac events in patients with coronary artery disease: a meta-analysis. Cardiovascular Diagnosis and Therapy, 2016, 6, 101-108.	0.7	3
316	Ticagrelor and heart surgery controversy: we may have better antiplatelet options. Journal of Thoracic Disease, 2016, 8, 3016-3019.	0.6	0
317	Percutaneous Coronary Intervention. , 2016, , 179-194.		7
318	New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?. Molecules, 2016, 21, 284.	1.7	2
319	Antiplatelet and Anticoagulation Treatment in Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndrome. Cardiology in Review, 2016, 24, 170-176.	0.6	2
320	Inhibition of proteaseâ€activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood. Journal of Thrombosis and Haemostasis, 2016, 14, 1642-1654.	1.9	42
322	Proteaseâ€activated receptor 4: from structure to function and back again. British Journal of Pharmacology, 2016, 173, 2952-2965.	2.7	42
325	A Critical Appraisal of Aspirin in Secondary Prevention. Circulation, 2016, 134, 1881-1906.	1.6	70
326	Prevalence of gastrointestinal helminth parasites of zoonotic significance in dogs and cats in lower Northern Thailand. Journal of Veterinary Medical Science, 2016, 78, 1779-1784.	0.3	31
327	Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. Heart, 2016, 102, 1221-1229.	1.2	3
328	Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Nonâ€“ST-Segmentâ€“Elevation Acute Coronary Syndromes Clinical Trials. Circulation, 2016, 133, 1560-1573.	1.6	17
329	Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial. American Heart Journal, 2016, 178, 1-8.	1.2	15
330	Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2016, 67, 2135-2144.	1.2	66
331	Continued vorapaxar versus withdrawed clopidogrel both on top of low dose aspirin in patients undergoing heart surgery: A call for randomized trial. International Journal of Cardiology, 2016, 215, 273-276.	0.8	1
332	Antiplatelet Management for Coronary Heart Disease: Advances and Challenges. Current Atherosclerosis Reports, 2016, 18, 35.	2.0	12
333	Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis. Circulation: Cardiovascular Interventions, 2016, 9, e003114.	1.4	14
334	Effect of age on efficacy and safety of vorapaxar in patients with nonâ€“ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. American Heart Journal, 2016, 178, 176-184.	1.2	5

#	Article	IF	Citations
335	Protease-activated receptors in hemostasis. Blood, 2016, 128, 169-177.	0.6	108
336	Predicted PAR1 inhibitors from multiple computational methods. Chemical Physics Letters, 2016, 659, 295-303.	1.2	2
337	Proteinase-activated receptors (PARs) as targets for antiplatelet therapy. Biochemical Society Transactions, 2016, 44, 606-612.	1.6	26
338	New directions for pharmacotherapy in the treatment of acute coronary syndrome. Expert Opinion on Pharmacotherapy, 2016, 17, 2291-2306.	0.9	15
339	Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks. Mayo Clinic Proceedings, 2016, 91, 1413-1447.	1.4	10
340	SePARating thrombosis and hemostasis?. Thrombosis Research, 2016, 145, 140-142.	0.8	1
341	Validation of Three Platelet Function Tests for Bleeding Risk Stratification During Dual Antiplatelet Therapy Following Coronary Interventions. Clinical Cardiology, 2016, 39, 385-390.	0.7	13
342	Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease. Nature Reviews Cardiology, 2016, 13, 609-622.	6.1	24
343	Development of a Series of (1-Benzyl-3-(6-methoxypyrimidin-3-yl)-5-(trifluoromethoxy)-1H-indol-2-yl)methanols as Selective Protease Activated Receptor 4 (PAR4) Antagonists with in Vivo Utility and Activity Against Î³-Thrombin. Journal of Medicinal Chemistry, 2016, 59, 7690-7695.	2.9	13
344	Antithrombotic Therapy for Secondary Prevention in Patients With Diabetes Mellitus and Coronary Artery Disease. Circulation Journal, 2016, 80, 791-801.	0.7	16
345	A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. American Heart Journal, 2016, 181, 92-100.	1.2	20
346	Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes. Heart, 2016, 102, 882-892.	1.2	3
347	Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. European Heart Journal, 2017, 38, ehw525.	1.0	164
348	Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. Thrombosis and Haemostasis, 2016, 115, 213-221.	1.8	9
349	Using Mendelian Randomization Studies to Assess Causality and Identify New Therapeutic Targets in Cardiovascular Medicine. Current Genetic Medicine Reports, 2016, 4, 207-212.	1.9	4
350	Vorapaxar. Coronary Artery Disease, 2016, 27, 604-615.	0.3	5
351	Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar. Catheterization and Cardiovascular Interventions, 2016, 88, 163-173.	0.7	7
352	Should the Dose of Antiplatelet Drugs Be Adjusted for Body Weight? The Example of Vorapaxar. Cardiology, 2016, 133, 69-72.	0.6	1

#	Article	IF	Citations
353	A Central Role for Monocyteâ€“Platelet Interactions in Heart Failure. Journal of Cardiovascular Pharmacology and Therapeutics, 2016, 21, 245-261.	1.0	22
354	High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating nonâ€“ST-segment elevation myocardial infarction. American Heart Journal, 2016, 171, 25-32.	1.2	11
355	Sudden Cardiac Death After Nonâ€“ST-Segment Elevation Acute Coronary Syndrome. JAMA Cardiology, 2016, 1, 73.	3.0	22
356	Targeting thrombin long-term after an acute coronary syndrome: Opportunities and challenges. Vascular Pharmacology, 2016, 81, 1-14.	1.0	8
357	Protease-Activated Receptor 4 Variant p.Tyr157Cys Reduces Platelet Functional Responses and Alters Receptor Trafficking. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 952-960.	1.1	18
358	Protease receptor antagonism to target blood platelet therapies. Clinical Pharmacology and Therapeutics, 2016, 99, 72-81.	2.3	10
359	A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. American Heart Journal, 2016, 174, 120-128.	1.2	29
360	Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2Â°P-TIMI 50). American Journal of Cardiology, 2016, 117, 1055-1058.	0.7	5
361	Vorapaxar monotherapy for secondary stroke prevention: A call for randomized trial. International Journal of Stroke, 2016, 11, 614-617.	2.9	3
362	Role of Vorapaxar After Coronary Revascularization. American Journal of Cardiology, 2016, 117, 1059-1064.	0.7	2
363	Indicaciones y duraciÃ³n de las combinaciones de antiagregantes. FMC Formacion Medica Continuada En Atencion Primaria, 2016, 23, 29-34.	0.0	0
364	Developing drugs for use before, during and soon after percutaneous coronary intervention. Expert Opinion on Pharmacotherapy, 2016, 17, 803-818.	0.9	14
365	In Vivo and protease-activated receptor-1-mediated platelet activation in patients presenting for cardiac catheterization. Platelets, 2016, 27, 308-316.	1.1	6
366	Pooled analysis of adverse event collection from 4 acute coronary syndrome trials. American Heart Journal, 2016, 174, 60-67.	1.2	4
367	Safety of Antithrombotic Agents in Elderly Patients with Acute Coronary Syndromes. Drugs and Aging, 2016, 33, 233-248.	1.3	6
368	Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage. Neurocritical Care, 2016, 24, 6-46.	1.2	550
369	The FDA review on data quality and conduct in vorapaxar trials: Much better than in PLATO, but still not perfect. International Journal of Cardiology, 2016, 205, 13-16.	0.8	1
370	Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 189-197.	1.1	89

#	Article	IF	Citations
371	Vorapaxar and optimal aspirin dose: The FDA outlook. International Journal of Cardiology, 2016, 203, 903-905.	0.8	2
372	Evaluation of the F2R IVS-14A/T PAR1 polymorphism with subsequent cardiovascular events and bleeding in patients who have undergone percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis, 2016, 41, 656-662.	1.0	7
373	Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2016, 34, 463-477.	1.7	2
374	Why does pre-clinical success in cardioprotection fail at the bedside?. Cardiovascular Research, 2016, 109, 189-190.	1.8	1
375	Update on oral antithrombotic therapy for secondary prevention following non-ST segment elevation myocardial infarction. Trends in Cardiovascular Medicine, 2016, 26, 321-334.	2.3	3
376	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2016, 37, 267-315.	1.0	5,890
377	Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 443-454.	0.4	43
378	Dysregulated protease activated receptor 1 (PAR1) promotes metastatic phenotype in breast cancer through HMGA2. Oncogene, 2016, 35, 1529-1540.	2.6	38
379	Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 155-163.	0.4	1
380	Protease-Activated Receptor 1 Inhibitors: Novel Antiplatelet Drugs in Prevention of Atherothrombosis. American Journal of Therapeutics, 2017, 24, e730-e736.	0.5	4
381	Vorapaxar and Amyotrophic Lateral Sclerosis: Coincidence or Adverse Association?. American Journal of Therapeutics, 2017, 24, e139-e143.	0.5	5
382	The Intracranial-B₂LEED₃S Score and the Risk of Intracranial Hemorrhage in Ischemic Stroke Patients Under Antiplatelet Treatment. Cerebrovascular Diseases, 2017, 43, 145-151.	0.8	17
383	Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease. Drugs in R and D, 2017, 17, 65-72.	1.1	33
384	Oral antiplatelet agents for the management of acute coronary syndromes. Journal of the American Association of Nurse Practitioners, 2017, 29, 104-115.	0.5	2
385	Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Nonâ€“ST-Elevation Acute Coronary Syndrome. Clinical Chemistry, 2017, 63, 573-584.	1.5	26
386	Targeting a Proteinase-Activated Receptor 4 (PAR4) Carboxyl Terminal Motif to Regulate Platelet Function. Molecular Pharmacology, 2017, 91, 287-295.	1.0	23
387	Antithrombotic therapy for patients with STEMI undergoing primary PCI. Nature Reviews Cardiology, 2017, 14, 361-379.	6.1	76
388	Oral antiplatelet drugs in patients with chronic kidney disease (CKD): a review. Journal of Thrombosis and Thrombolysis, 2017, 43, 519-527.	1.0	10

#	Article	IF	Citations
389	Pharmacokinetic drug evaluation of vorapaxar for secondary prevention after acute coronary syndrome. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 339-350.	1.5	2
390	An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome. American Heart Journal, 2017, 187, 53-61.	1.2	33
391	Bleeding associated with the management of acute coronary syndromes. Heart, 2017, 103, 546-562.	1.2	5
392	The Effect of Combined Aspirin and Clopidogrel Treatment on Cancer Incidence. American Journal of Medicine, 2017, 130, 826-832.	0.6	48
393	Letter by Lozano et al Regarding Article, â€œPrasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Multicenter Randomized PRAGUE-18 Studyâ€• Circulation, 2017, 135, e885-e886.	1.6	0
394	Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites. American Journal of Medicine, 2017, 130, 1170-1176.	0.6	8
395	First, do no (irreparable) harm: infarction, bleeding, and subsequent risk of death. The dangers of false equivalency. European Heart Journal, 2017, 38, ehw639.	1.0	0
396	Improving outcome in acute coronary syndromes: ischaemic conditioning, antithrombosis and bleeding, and inflammasome antagonism. European Heart Journal, 2017, 38, 763-766.	1.0	1
397	Vorapaxar in secondary prevention: where we stand. Current Medical Research and Opinion, 2017, 33, 2077-2079.	0.9	1
398	Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease. European Journal of Preventive Cardiology, 2017, 24, 61-70.	0.8	20
399	Vorapaxar in the long-term secondary prevention of atherothrombotic events: a profile of its use in the USA. Drugs and Therapy Perspectives, 2017, 33, 254-259.	0.3	0
400	A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization. Circulation, 2017, 135, 2534-2555.	1.6	136
401	Oral antiplatelet therapy: impact for transfusion medicine. Vox Sanguinis, 2017, 112, 511-517.	0.7	11
402	Targeting PAR1: Now What?. Trends in Pharmacological Sciences, 2017, 38, 701-716.	4.0	70
403	Recurrent MI and stroke postâ€“acute coronary syndrome: Which is the lesser evil?. American Heart Journal, 2017, 187, 191-193.	1.2	1
404	Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes. Heart, 2017, 103, 1168-1176.	1.2	34
405	The risk of bleeding with the use of antiplatelet agents for the treatment of cardiovascular disease. Expert Opinion on Drug Safety, 2017, 16, 561-572.	1.0	21
406	Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome. American Heart Journal, 2017, 187, 194-203.	1.2	26

#	Article	IF	Citations
407	Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis. International Journal of Cardiology, 2017, 241, 87-96.	0.8	24
408	Statistical planning to address strongly correlated endpoints for inferential subgroups: An innovative approach for an illustrative clinical trial with complex multiplicity issues. Journal of Biopharmaceutical Statistics, 2017, 27, 399-415.	0.4	2
409	Protease-Activated Receptor-1 Antagonists Post-Percutaneous Coronary Intervention. Interventional Cardiology Clinics, 2017, 6, 57-66.	0.2	1
410	Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	6
411	Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding. Science Translational Medicine, 2017, 9, .	5.8	124
412	Contributions of Protease-Activated Receptors PAR1 and PAR4 to Thrombin-Induced GPIIbIIIa Activation in Human Platelets. Molecular Pharmacology, 2017, 91, 39-47.	1.0	29
413	Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. Journal of the American College of Cardiology, 2017, 70, 1760-1776.	1.2	140
414	Docking based design of diastereoisomeric MTCA as GPIIb/IIIa receptor inhibitor. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 5114-5118.	1.0	4
415	Contemporary Use of Oral Antithrombotic Agents: Focus on Dual and Triple Therapeutic Approaches. Pharmacotherapy, 2017, 37, 1545-1564.	1.2	0
416	CRUSADE Score is Superior to Platelet Function Testing for Prediction of Bleeding in Patients Following Coronary Interventions. EBioMedicine, 2017, 21, 213-217.	2.7	3
417	TGFâ€î² induced PARâ€‚1 expression promotes tumor progression and osteoclast differentiation in giant cell tumor of bone. International Journal of Cancer, 2017, 141, 1630-1642.	2.3	17
418	Discovery of Potent Orally Active Protease-Activated Receptor 1 (PAR1) Antagonists Based on Andrographolide. Journal of Medicinal Chemistry, 2017, 60, 7166-7185.	2.9	16
419	Update on antithrombotic therapy after percutaneous coronary revascularisation. Lancet, The, 2017, 390, 810-820.	6.3	25
420	Platelet pathophysiology, pharmacology, and function in coronary artery disease. Coronary Artery Disease, 2017, 28, 614-623.	0.3	22
422	Safety and efficacy of vorapaxar in secondary prevention of atherosclerotic disease: A meta-analysis of randomized control trials. International Journal of Cardiology, 2017, 227, 617-624.	0.8	16
423	Increased Benefit With Vorapaxar Use in Patients With a History of Myocardial Infarction and Diabetes Mellitus. Journal of Cardiovascular Pharmacology and Therapeutics, 2017, 22, 133-141.	1.0	2
424	Therapeutic strategies for atherosclerosis and atherothrombosis: Past, present and future. Thrombosis and Haemostasis, 2017, 117, 1258-1264.	1.8	40
425	Antithrombotic therapy for acute coronary syndrome: Past, present and future. Thrombosis and Haemostasis, 2017, 117, 1240-1248.	1.8	41

#	Article	IF	Citations
426	Platelets, Haemostasis and Inflammation. Cardiac and Vascular Biology, 2017, , .	0.2	5
427	Platelets and Stroke. Cardiac and Vascular Biology, 2017, , 253-274.	0.2	1
428	Platelet receptors as therapeutic targets: Past, present and future. Thrombosis and Haemostasis, 2017, 117, 1249-1257.	1.8	57
429	Clinical pathways and management of antithrombotic therapy in patients with acute coronary syndrome (ACS): a Consensus Document from the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Society of Emergency Medicine (SIMEU) and Italian Society of Interventional Cardiology (SICI-GISE). European Heart Journal Supplements, 2017, 19, D130-D150.	0.0	4
430	STAT3 in Pancreatic Cancer Metastasis. , 2017, , 351-361.		1
431	Advances in Antiplatelet Agents. , 2017, , 556-599.		1
432	Oral anticoagulant use in cardiovascular disorders: a perspective on present and potential indications for rivaroxaban. Current Medical Research and Opinion, 2018, 34, 1945-1957.	0.9	2
433	Optimal pharmacological therapy in ST-elevation myocardial infarctionâ€”aÂreview. Netherlands Heart Journal, 2018, 26, 296-310.	0.3	12
434	Plasma contact factors as therapeutic targets. Blood Reviews, 2018, 32, 433-448.	2.8	50
435	Combination oral antithrombotic therapy for the treatment of myocardial infarction: recent developments. Expert Opinion on Pharmacotherapy, 2018, 19, 653-665.	0.9	15
436	Noncanonical Matrix Metalloprotease 1â€“Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 1368-1380.	1.1	38
437	PAR4 (Protease-Activated Receptor 4). Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 287-289.	1.1	23
438	Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention After Acute Coronary Syndromes. JAMA Cardiology, 2018, 3, 234.	3.0	46
439	Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 726-732.	1.1	20
440	More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapyâ€”Current Data and Future Directions. Journal of the American Heart Association, 2018, 7, .	1.6	11
442	PAR1 agonists stimulate APC-like endothelial cytoprotection and confer resistance to thromboinflammatory injury. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E982-E991.	3.3	55
443	Protease-activated receptor-4 (PAR4) variant influences on platelet reactivity induced by PAR4-activating peptide through altered Ca2+ mobilization and ERK phosphorylation in healthy Japanese subjects. Thrombosis Research, 2018, 162, 44-52.	0.8	17
444	PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 448-456.	1.1	79

#	Article	IF	Citations
445	Current and future antiplatelet therapies: emphasis on preserving haemostasis. Nature Reviews Cardiology, 2018, 15, 181-191.	6.1	207
446	New and upcoming treatments in antiphospholipid syndrome: A comprehensive review. Pharmacological Research, 2018, 133, 108-120.	3.1	7
447	Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study. Journal of Thrombosis and Thrombolysis, 2018, 45, 469-476.	1.0	11
448	Platelet Signaling Pathways and New Inhibitors. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, e28-e35.	1.1	41
449	Rivaroxaban: A New Treatment Paradigm in the Setting of Vascular Protection?. Thrombosis and Haemostasis, 2018, 118, S12-S22.	1.8	23
450	Clinical effects with inhibition of multiple coagulative pathways in patients admitted for acute coronary syndrome. Internal and Emergency Medicine, 2018, 13, 1019-1028.	1.0	2
451	No Pharmacokinetic Drugâ€“Drug Interaction Between Prasugrel and Vorapaxar Following Multipleâ€Đose Administration in Healthy Volunteers. Clinical Pharmacology in Drug Development, 2018, 7, 143-150.	0.8	2
453	Antiplatelet and Anticoagulant Drugs. , 2018, , 303-320.		1
454	Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside. Journal of Cardiovascular Pharmacology and Therapeutics, 2018, 23, 23-37.	1.0	17
455	The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts. Expert Review of Hematology, 2018, 11, 5-12.	1.0	17
456	Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice?. Platelets, 2018, 29, 228-237.	1.1	3
457	Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. American Heart Journal, 2018, 196, 28-35.	1.2	10
458	The platelet phenotype in patients with ST-segment elevation myocardial infarction is different from nonâ€“ST-segment elevation myocardial infarction. Translational Research, 2018, 195, 1-12.	2.2	19
460	Vorapaxar treatment reduces mesangial expansion in streptozotocin-induced diabetic nephropathy in mice. Oncotarget, 2018, 9, 21655-21662.	0.8	10
461	Antiplatelet therapy for peripheral artery disease. Cardiovascular Diagnosis and Therapy, 2018, 8, 663-677.	0.7	9
462	Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial. Journal of the American Heart Association, 2018, 7, e009609.	1.6	9
463	Diabetes and antiplatelet therapy: from bench to bedside. Cardiovascular Diagnosis and Therapy, 2018, 8, 594-609.	0.7	45
464	Days Alive and Out of Hospital: Exploring a Patient-Centered, Pragmatic Outcome in a Clinical Trial of Patients With Acute Coronary Syndromes. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004755.	0.9	51

#	Article	IF	Citations
465	Platelet CD36 signaling through ERK5 promotes caspase-dependent procoagulant activity and fibrin deposition in vivo. Blood Advances, 2018, 2, 2848-2861.	2.5	44
466	OBSOLETE: Vascular Repair at the Interface of the Endothelium: The Roles of Protease-Activated Receptors and Neuregulin-1. , 2018, , .		0
467	Recomendaciones del manejo antiagregante en CardiologÃa. Documento de revisiÃ³n de la Sociedad Andaluza de CardiologÃa. Cardiocore, 2018, 53, e13-e31.	0.0	0
468	Gender differences on benefits and risks associated with oral antithrombotic medications for coronary artery disease. Expert Opinion on Drug Safety, 2018, 17, 1041-1052.	1.0	20
469	Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial. Lancet HIV,the, 2018, 5, e553-e559.	2.1	19
471	Reversal of Systemic Anticoagulants and Antiplatelet Therapeutics. Neurosurgery Clinics of North America, 2018, 29, 537-545.	0.8	11
472	Vascular Repair at the Interface of the Endothelium: The Roles of Protease-Activated Receptors and Neuregulin-1. , 2018, , 627-639.		0
473	A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant. Blood Advances, 2018, 2, 1283-1293.	2.5	24
474	Antithrombotic Therapy for PeripheralÂArtery Disease. Journal of the American College of Cardiology, 2018, 71, 2450-2467.	1.2	43
475	Diabetes and Cardiovascular Disease. , 2018, , 823-838.		0
476	Astrocytes and the Warning Signs of Intracerebral Hemorrhagic Stroke. Neural Plasticity, 2018, 2018, 1-11.	1.0	25
477	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nature Reviews Cardiology, 2018, 15, 480-496.	6.1	180
478	Antithrombotic Drugs. , 2018, , 2168-2188.		5
479	Protease-Activated Receptor 1 as Therapeutic Target in Breast, Lung, and Ovarian Cancer: Pepducin Approach. International Journal of Molecular Sciences, 2018, 19, 2237.	1.8	41
480	Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. Blood Cells, Molecules, and Diseases, 2018, 72, 37-43.	0.6	10
481	Antiplatelet Therapy in Coronary Artery Disease: A Daunting Dilemma. Journal of Clinical Medicine, 2018, 7, 74.	1.0	5
482	Oral Antiplatelet Therapy for Secondary Prevention of Acute Coronary Syndrome. American Journal of Cardiovascular Drugs, 2018, 18, 457-472.	1.0	13
483	Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome. American Heart Journal, 2018, 201, 25-32.	1.2	9

#	Article	IF	Citations
484	Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With PercutaneousÂCoronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 856-864.	1.1	25
485	Peri-Procedural Platelet Reactivity in Percutaneous Coronary Intervention. Thrombosis and Haemostasis, 2018, 118, 1131-1140.	1.8	11
486	Inhibition of Protease-Activated Receptor (PAR1) Reduces Activation of the Endothelium, Coagulation, Fibrinolysis and Inflammation during Human Endotoxemia. Thrombosis and Haemostasis, 2018, 118, 1176-1184.	1.8	33
487	Inhibition of high shear arterial thrombosis by charged nanoparticles. Biomicrofluidics, 2018, 12, 042210.	1.2	22
488	Antiplatelet and anticoagulation therapy during percutaneous coronary interventions: A review for the interventionalist. Journal of Interventional Cardiology, 2018, 31, 693-704.	0.5	2
489	Anti-platelet drugs and their necessary interaction with endothelial mediators and platelet cyclic nucleotides for therapeutic efficacy. , 2019, 193, 83-90.		16
490	Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?. European Heart Journal, 2019, 40, 1466-1471.	1.0	22
491	2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2019, 40, 87-165.	1.0	4,537
492	2018 ESC/EACTS Guidelines on myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2019, 55, 4-90.	0.6	402
493	Targeting coagulation in heart failure with preserved ejection fraction and cardiac fibrosis. European Heart Journal, 2019, 40, 3333-3335.	1.0	3
494	Proteaseâ€activated receptorâ€mediated platelet aggregation in acute coronary syndrome patients on potent P2Y12 inhibitors. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 383-390.	1.0	18
495	Pharmacological PARâ€1 inhibition reduces blood glucose levels but does not improve kidney function in experimental type 2 diabetic nephropathy. FASEB Journal, 2019, 33, 10966-10972.	0.2	7
496	Association Between ApoA-I (Apolipoprotein A-I) Immune Complexes and Adverse Cardiovascular Eventsâ€"Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1884-1892.	1.1	7
497	Non-ST Elevation Myocardial Infarction: Diagnosis and Management. , 0, , .		3
498	Protease-Activated Receptors 1 and 3 are Differentially Expressed on Human Monocyte Subsets and are Upregulated by Lipopolysaccharide Ex Vivo and In Vivo. Thrombosis and Haemostasis, 2019, 119, 1394-1402.	1.8	4
499	Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic Efficacy. Journal of Medicinal Chemistry, 2019, 62, 7400-7416.	2.9	12
500	Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms. Expert Opinion on Drug Safety, 2019, 18, 1171-1189.	1.0	23
501	Therapeutic Vaccines as Novel Immunotherapy. , 2019, , .		1

#	Article	IF	Citations
502	Antiplatelet Agents for Cancer Prevention: Current Evidences and Continuing Controversies. Cancers, 2019, 11, 1639.	1.7	9
503	Cardiovascular Risk Factors and Secondary Events Among Acute and Chronic Stable Myocardial Infarction Patients: Findings from a Managed Care Database. Cardiology and Therapy, 2019, 8, 329-343.	1.1	3
504	Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention after Acute Coronary Syndromes: a Review. Current Cardiology Reports, 2019, 21, 5.	1.3	2
505	The Two-way Relationship Between Cancer and Atherosclerosis. Revista Espanola De Cardiologia (English Ed), 2019, 72, 487-494.	0.4	14
506	Antithrombotic Therapy After Revascularization in Patients With Peripheral Arterial Disease: What Is Here, What Is Next. Vascular and Endovascular Surgery, 2019, 53, 325-336.	0.3	2
507	Safety and Efficacy of Rivaroxaban When Added to Aspirin Monotherapy Among Stabilized Postâ€Acute Coronary Syndrome Patients: A Pooled Analysis Study of ATLAS ACSâ€TIMI 46 and ATLAS ACS 2â€TIMI 51. Journal of the American Heart Association, 2019, 8, .	1.6	10
508	Protease-Activated Receptors. , 2019, , 243-257.		8
509	Laboratory Monitoring of Antiplatelet Therapy. , 2019, , 653-682.		0
510	PAR-1 Antagonists. , 2019, , 973-977.		1
511	Novel Antiplatelet Therapies. , 2019, , 991-1015.		1
512	Antiplatelet Drugs in the Management of Coronary Artery Disease. , 2019, , 1017-1029.		0
513	Development of New Antithrombotic Regimens for Patients with Acute CoronaryÂSyndrome. Clinical Drug Investigation, 2019, 39, 495-502.	1.1	3
514	A vaccine targeting blood clot formation: what is the potential?. Expert Review of Vaccines, 2019, 18, 419-421.	2.0	0
515	Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases. Thrombosis Journal, 2019, 17, 4.	0.9	200
516	Cooling therapy for the management of hypoxic-ischaemic encephalopathy in middle-income countries: we can, but should we?. Paediatrics and International Child Health, 2019, 39, 231-233.	0.3	10
517	La relaciÃ³n bidireccional entre el cÃ¡ncer y la ateroesclerosis. Revista Espanola De Cardiologia, 2019, 72, 487-494.	0.6	15
518	Pharmacological Inhibition of Serine Proteases to Reduce Cardiac Inflammation and Fibrosis in Atrial Fibrillation. Frontiers in Pharmacology, 2019, 10, 1420.	1.6	12
519	Role of the coagulation system in the pathogenesis of sickle cell disease. Blood Advances, 2019, 3, 3170-3180.	2.5	38

#	Article	IF	Citations
520	Using PAR4 Inhibition as an Anti-Thrombotic Approach: Why, How, and When?. International Journal of Molecular Sciences, 2019, 20, 5629.	1.8	20
521	Assessing bleeding in acute coronary syndrome using the Bleeding Academic Research Consortium definition. Journal of Cardiovascular Medicine, 2019, 20, 818-824.	0.6	3
522	Oral antiplatelets in primary and secondary prevention of myocardial infarction: a review. Irish Journal of Medical Science, 2019, 188, 453-467.	0.8	4
523	Investigational drugs for the treatment of acute myocardial infarction: focus on antiplatelet and anticoagulant agents. Expert Opinion on Investigational Drugs, 2019, 28, 223-234.	1.9	7
524	Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. Circulation, 2019, 139, 863-873.	1.6	18
525	Antiplatelet Therapy. , 2019, , 379-393.e4.		1
526	Impaired endogenous fibrinolysis in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention is a predictor of recurrent cardiovascular events: the RISK PPCI study. European Heart Journal, 2019, 40, 295-305.	1.0	61
527	Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease. JAMA Cardiology, 2019, 4, 7.	3.0	26
528	Unstable Angina and Non-ST Elevation Myocardial Infarction. Contemporary Cardiology, 2019, , 233-259.	0.0	0
529	Antiplatelet Therapy in Cardiovascular Medicine. , 2019, , 396-414.		0
530	Antimicrobial Peptide Cathelicidin-BF Inhibits Platelet Aggregation by Blocking Protease-Activated Receptor 4. International Journal of Peptide Research and Therapeutics, 2019, 25, 349-358.	0.9	8
531	Acquired platelet function disorders. Thrombosis Research, 2020, 196, 561-568.	0.8	8
532	Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 86-93.	1.4	27
533	The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 97-103.	1.4	14
534	Molecular basis of proteaseâ€activated receptor 1 signaling diversity. Journal of Thrombosis and Haemostasis, 2020, 18, 6-16.	1.9	44
535	Rationale and design of â€œCan Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)â€•study. Journal of Thrombosis and Thrombolysis, 2020, 49, 192-198.	1.0	6
536	A double-blind, randomized, placebo-controlled pilot trial to evaluate safety and efficacy of vorapaxar on arteriovenous fistula maturation. Journal of Vascular Access, 2020, 21, 467-474.	0.5	1
537	Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa-Driven Platelet Activation via Protease Activated Receptor-1. Circulation Research, 2020, 126, 486-500.	2.0	87

#	Article	IF	Citations
538	Antithrombotic strategies for patients with coronary and lower extremity peripheral artery diseases: a narrative review. Expert Review of Cardiovascular Therapy, 2020, 18, 881-889.	0.6	3
539	PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 2990-3003.	1.1	18
540	Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy. Atherosclerosis, 2020, 315, 10-17.	0.4	17
541	Lipid Receptor GPR31 (G-Proteinâ€"Coupled Receptor 31) Regulates Platelet Reactivity and Thrombosis Without Affecting Hemostasis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, e33-e45.	1.1	15
542	New and emerging cardiovascular and antihypertensive drugs. Expert Opinion on Drug Safety, 2020, 19, 1315-1327.	1.0	5
543	Determination of PAR4 numbers on the surface of human platelets: no effect of the single nucleotide polymorphism rs773902. Platelets, 2020, 32, 1-4.	1.1	2
544	Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity?. Cardiovascular Drugs and Therapy, 2021, 35, 1183-1190.	1.3	1
545	Clinical Significance of Thrombin Blockade with Low Doses (2.5 mg) of Rivaroxaban in Ischemic Heart Disease Patients. Rational Pharmacotherapy in Cardiology, 2020, 16, 99-107.	0.3	0
546	Vorapaxar in the treatment of cardiovascular diseases. Future Cardiology, 2020, 16, 373-384.	0.5	10
547	Loss of Protease-Activated Receptor 4 Prevents Inflammation Resolution and Predisposes the Heart to Cardiac Rupture After Myocardial Infarction. Circulation, 2020, 142, 758-775.	1.6	14
548	Novel Mouse Model for Studying Hemostatic Function of Human Platelets. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1891-1904.	1.1	7
549	Antiplatelet therapies in diabetes. Diabetic Medicine, 2020, 37, 726-734.	1.2	2
550	Dual blockade of protease-activated receptor 1 and 2 additively ameliorates diabetic kidney disease. American Journal of Physiology - Renal Physiology, 2020, 318, F1067-F1073.	1.3	13
551	Therapeutic strategies for thrombosis: new targets and approaches. Nature Reviews Drug Discovery, 2020, 19, 333-352.	21.5	188
552	Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. Journal of the American College of Cardiology, 2020, 76, 162-171.	1.2	50
553	New Antithrombotic Drugs in Acute Coronary Syndrome. Journal of Clinical Medicine, 2020, 9, 2059.	1.0	10
554	A Platelet Function Modulator of Thrombin Activation Is Causally Linked to Cardiovascular Disease and Affects PAR4 Receptor Signaling. American Journal of Human Genetics, 2020, 107, 211-221.	2.6	26
555	Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence. Thrombosis and Haemostasis, 2020, 120, 1147-1158.	1.8	23

#	Article	IF	Citations
556	Ticagrelor Inhibits Toll-Like and Protease-Activated Receptor Mediated Platelet Activation in Acute Coronary Syndromes. Cardiovascular Drugs and Therapy, 2020, 34, 53-63.	1.3	20
557	Novel Antiplatelet Agents in Cardiovascular Disease. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 191-200.	1.0	28
558	Tackling Elevated Risk in PAD: Focus on Antithrombotic and Lipid Therapy for PAD. Current Cardiology Reports, 2020, 22, 13.	1.3	1
559	Contribution of social factors to readmissions within 30 days after hospitalization for COPD exacerbation. BMC Pulmonary Medicine, 2020, 20, 107.	0.8	13
561	Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y₁₂Receptor Inhibitors With and Without Aspirin: Results of the VORAâ€PRATIC Study. Journal of the American Heart Association, 2020, 9, e015865.	1.6	18
562	Novel antiplatelet targets in the treatment of acute coronary syndromes. Platelets, 2021, 32, 15-28.	1.1	20
563	Mechanistic Insights to Target Atherosclerosis Residual Risk. Current Problems in Cardiology, 2021, 46, 100432.	1.1	21
564	Protease-Activated Receptors (PARs). , 2021, , 1-13.		0
565	Safety of antithrombotic therapy in East Asian patients. Internal and Emergency Medicine, 2021, 16, 1443-1450.	1.0	7
566	Improving Outcomes in Cardiovascular Diseases. Cardiology in Review, 2021, Publish Ahead of Print, .	0.6	4
567	Antithrombotic Therapy in Patients with Coronary Artery Disease and Prior Stroke. Journal of Clinical Medicine, 2021, 10, 1923.	1.0	3
568	Oral Antiplatelet Therapy After Acute Coronary Syndrome. JAMA - Journal of the American Medical Association, 2021, 325, 1545.	3.8	62
569	Aspirin at 120: Retiring, recombining, or repurposing?. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12516.	1.0	6
570	New Insights Into Platelet-enriched miRNAs: Production, Functions, Roles in Tumors, and Potential Targets for Tumor Diagnosis and Treatment. Molecular Cancer Therapeutics, 2021, 20, 1359-1366.	1.9	6
571	Do we have a unified consensus on antithrombotic management of PAD?. International Angiology, 2021, 40, 229-239.	0.4	1
572	Negatively charged nanoparticles of multiple materials inhibit shear-induced platelet accumulation. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 35, 102405.	1.7	2
573	Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials. JAMA Network Open, 2021, 4, e2117963.	2.8	5
574	Effects of Heparin and Bivalirudin on Thrombin-Induced Platelet Activation: Differential Modulation of PAR Signaling Drives Divergent Prothrombotic Responses. Frontiers in Cardiovascular Medicine, 2021, 8, 717835.	1.1	4

#	Article	IF	Citations
575	Prevalence of atherosclerotic cardiovascular disease and subsequent major adverse cardiovascular events in <scp>Alberta, Canada</scp>: A realâ€world evidence study. Clinical Cardiology, 2021, 44, 1613-1620.	0.7	17
576	Platelet physiology and pharmacologyâ€"relevant considerations for patient care. , 2021, , 15-45.		0
577	PAR Antagonists. , 2017, , 1299-1311.		1
578	15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report. , 2017, , 317-338.		19
579	Oral antiplatelet agents in cardiovascular disease. Vasa - European Journal of Vascular Medicine, 2019, 48, 291-302.	0.6	14
580	Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey. European Heart Journal, 2021, 42, 339-351.	1.0	57
581	Protease-Activated Receptor PAR-4: An Inducible Switch between Thrombosis and Vascular Inflammation?. Thrombosis and Haemostasis, 2017, 117, 2013-2025.	1.8	31
582	Sex-Specific Platelet Activation Through Protease-Activated Receptors Reverses in Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 390-400.	1.1	11
583	Platelet-targeted dual pathway antithrombotic inhibits thrombosis with preserved hemostasis. JCI Insight, 2018, 3, .	2.3	23
584	PAR1 contributes to influenza A virus pathogenicity in mice. Journal of Clinical Investigation, 2013, 123, 206-214.	3.9	73
585	PAR-1 contributes to the innate immune response during viral infection. Journal of Clinical Investigation, 2013, 123, 1310-1322.	3.9	128
586	Update on pharmacological treatment of acute coronary syndrome without persistent ST segment elevation myocardial infarction in the elderly. Journal of Geriatric Cardiology, 2017, 14, 457-464.	0.2	4
587	Synthesis of Indole Derived Protease-Activated Receptor 4 Antagonists and Characterization in Human Platelets. PLoS ONE, 2013, 8, e65528.	1.1	27
588	Role of Opioid Receptors Signaling in Remote Electrostimulation - Induced Protection against Ischemia/Reperfusion Injury in Rat Hearts. PLoS ONE, 2015, 10, e0138108.	1.1	8
589	Identification and Characterization of Novel Variations in Platelet G-Protein Coupled Receptor (GPCR) Genes in Patients Historically Diagnosed with Type 1 von Willebrand Disease. PLoS ONE, 2015, 10, e0143913.	1.1	6
590	Humanizing the Protease-Activated Receptor (PAR) Expression Profile in Mouse Platelets by Knocking PAR1 into the Par3 Locus Reveals PAR1 Expression Is Not Tolerated in Mouse Platelets. PLoS ONE, 2016, 11, e0165565.	1.1	16
591	Optimum Utilisation of Novel Antiplatelet Agents in Clinical Practice. Interventional Cardiology Review, 2014, 9, 164.	0.7	1
592	Dual antiplatelet therapy with clopidogrel and aspirin increases mortality in 4T1 metastatic breast cancer-bearing mice by inducing vascular mimicry in primary tumour. Oncotarget, 2018, 9, 17810-17824.	0.8	28

#	Article	IF	Citations
593	Drugs targeting protease-activated receptor-4 improve the anti-thrombotic therapeutic window. Annals of Translational Medicine, 2017, 5, 464-464.	0.7	7
594	Antithrombotic Treatment in Diabetes Mellitus: A Review of the Literature about Antiplatelet and Anticoagulation Strategies Used for Diabetic Patients in Primary and Secondary Prevention. Current Pharmaceutical Design, 2020, 26, 2780-2788.	0.9	14
595	Antiplatelet agents in clinical practice and their haemorrhagic risk. Blood Transfusion, 2013, 11, 349-56.	0.3	20
596	Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention. Ecancermedicalscience, 2020, 14, 998.	0.6	4
597	Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction. Journal of Pharmacy and Bioallied Sciences, 2016, 8, 98.	0.2	4
598	Oral antithrombotic therapy after acute coronary syndromes: â€œdual antiplateletâ€•or â€œdual pathwayâ€?. EuroIntervention, 2017, 13, 773-775.	1.4	4
599	Antithrombotic and antiplatelet therapy in TAVI patients: a fallow field?. EuroIntervention, 2013, 9, S43-S47.	1.4	11
600	2018 ESC/EACTS Guidelines on myocardial revascularization. EuroIntervention, 2019, 14, 1435-1534.	1.4	367
601	Atopaxar. Hamostaseologie, 2012, 32, 228-233.	0.9	2
602	The Evolving Concept of Neuro-Thromboinflammation for Neurodegenerative Disorders and Neurotrauma: A Rationale for PAR1-Targeting Therapies. Biomolecules, 2021, 11, 1558.	1.8	1
603	Endogenous fibrinolysis inhibitors in acute coronary syndrome. American Heart Journal Plus, 2021, 10, 100058.	0.3	0
604	No benefit of vorapaxar on walking performance in patients with intermittent claudication. Vascular Medicine, 2021, , 1358863X2110420.	0.8	0
605	Platelets Contribution to Thrombin Generation in Philadelphia-Negative Myeloproliferative Neoplasms: The â€œCirculating Woundâ€•Model. International Journal of Molecular Sciences, 2021, 22, 11343.	1.8	4
606	Anti-coagulation and anti-platelet therapy for heart disease. Japanese Journal of Thrombosis and Hemostasis, 2012, 23, 25-32.	0.1	0
607	PAR-1 thrombin receptor antagonist. Japanese Journal of Thrombosis and Hemostasis, 2012, 23, 47-50.	0.1	0
611	Role of Antiplatelet Therapies in Preventing Atherothrombosis. Journal of Hematology & Thromboembolic Diseases, 2013, 01, .	0.1	1
612	Agents antiplaquettaires et athÃ©rothrombose. Bulletin De L'Academie Nationale De Medecine, 2013, 197, 375-388.	0.0	0
613	Anticoagulation Therapy. Heparins, Factor II and Factor Xa Inhibitors. , 2014, , 59-122.		0

#	Article	IF	Citations
614	Antiplatelet Drugs in the Management of Cardiovascular Indications. , 2014, , 1-24.		0
615	Impact of Selection Criteria on Outcomes of Antithrombotic Trials in Acute Coronary Syndromes. Journal of Clinical Trials, 2015, 05, .	0.1	0
616	Seven-transmembrane receptors. Japanese Journal of Thrombosis and Hemostasis, 2015, 26, 17-20.	0.1	0
617	Adding a New Anticoagulant or Antiplatelet Agent for Patient Receiving Aspirin after an Acute Coronary Syndrome?--Results from a Pairwise and Network Meta-Analysis of Randomized-Controlled Trials. British Journal of Medicine and Medical Research, 2015, 6, 173-199.	0.2	0
618	Monitoring Committee Structure and Function. , 2015, , 343-372.		0
619	Diplopia on vorapaxar: An unexpected side effect emerging only at second glance. Thrombosis and Haemostasis, 2016, 115, 911-912.	1.8	0
620	Overview of antiplatelet and anticoagulant therapy after acute myocardial infarction. Intervencni A Akutni Kardiologie, 2016, 15, 45-50.	0.0	0
621	Novedades en la evaluaciÃ³n del riesgo hemorrÃ¡gico del paciente con cardiopatÃa isquÃ©mica. Revista Espanola De Cardiologia Suplementos, 2017, 17, 16-23.	0.2	2
622	Platelets in Acute Coronary Syndromes. , 2017, , 1015-1028.		0
624	Data Monitoring: Structure for Clinical Trials and Sequential Monitoring Procedures. ICSA Book Series in Statistics, 2018, , 235-267.	0.0	0
625	Antiplatelet Therapy in Cardiovascular Disease. , 2019, , 195-207.		0
627	A Vaccine for Ischemic Stroke. , 2019, , 21-32.		0
629	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ NATIONAL SOCIETY OF HEART FAILURE AND MYOCARDIAL DISEASE (NSHFMD) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE (2020). Eurasian Heart Journal, 2020, , 6-76.	0.2	6
630	Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events â€“ A Review on Vorapaxar. Current Problems in Cardiology, 2023, 48, 101035.	1.1	4
631	Platelets in the Pathogenesis of Vascular Disease and Their Role as a Therapeutic Target. , 2020, , 233-261.		0
632	Controversies in the use & implementation of drug-eluting stent technology. Indian Journal of Medical Research, 2012, 136, 926-41.	0.4	0
633	Antithrombotic treatment tailoring and risk score evaluation in elderly patients diagnosed with an acute coronary syndrome. Journal of Geriatric Cardiology, 2017, 14, 442-456.	0.2	7
634	Sex-specific platelet activation through protease-activated receptor-1 in patients undergoing cardiac catheterization. Atherosclerosis, 2021, 339, 12-19.	0.4	4

#	Article	IF	Citations
635	The PAR4 Platelet Thrombin Receptor Variant rs773902 does not Impact the Incidence of Thrombotic or Bleeding Events in a Healthy Older Population. Thrombosis and Haemostasis, 2022, 122, 1130-1138.	1.8	1
636	Protease-Activated Receptors (PARs). , 2021, , 1277-1288.		0
637	Evaluation of the Role of Antiplatelet Medications in Cardiovascular Disease. Pharmacophore, 2021, 12, 97-103.	0.2	3
638	Antiplatelet Therapy for Atherothrombotic Disease in 2022â€"From Population to Patient-Centered Approaches. Frontiers in Cardiovascular Medicine, 2022, 9, 805525.	1.1	12
639	Peripheral versus central venous blood sampling does not influence the assessment of platelet activation in cirrhosis. Platelets, 2022, 33, 879-886.	1.1	5
640	Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases. International Journal of Molecular Sciences, 2021, 22, 13079.	1.8	20
641	The Evolution of Antiplatelet Therapy After Percutaneous Coronary Interventions: A 40-Year Journey. Canadian Journal of Cardiology, 2022, 38, S79-S88.	0.8	6
642	An optimized agonist peptide of protease-activated receptor 4 and its use in a validated platelet-aggregation assay. Platelets, 2022, 33, 979-986.	1.1	3
643	Factors Associated with Platelet Activation-Recent Pharmaceutical Approaches. International Journal of Molecular Sciences, 2022, 23, 3301.	1.8	7
645	Growth Differentiation Factor-15 Correlates Inversely with Protease-Activated Receptor-1-Mediated Platelet Reactivity in Patients with Left Ventricular Assist Devices. Pharmaceuticals, 2022, 15, 484.	1.7	4
646	Has Unstable Angina Become a Vestigial of the Past in Clinical Trial Primary Endpoints?. Cardiology, 2022, , .	0.6	0
648	Antiplatelet Therapy in Atherothrombotic Diseases: Similarities and Differences Across Guidelines. Frontiers in Pharmacology, 2022, 13, 878416.	1.6	2
649	P2Y12 Antagonists in Cardiovascular Diseaseâ€"Finding the Best Balance Between Preventing Ischemic Events and Causing Bleeding. Frontiers in Cardiovascular Medicine, 2022, 9, .	1.1	0
650	Event Rates and Risk Factors for Recurrent Cardiovascular Events and Mortality in a Contemporary Post Acute Coronary Syndrome Population Representing 239Â234 Patients During 2005 to 2018 in the United States. Journal of the American Heart Association, 2022, 11, e022198.	1.6	26
651	Unstable Angina as a Component of Primary Composite Endpoints in Clinical Cardiovascular Trials: Pros and Cons. Cardiology, 2022, , .	0.6	5
653	Investigational drugs for ischemic stroke: whatâ€™s in the clinical development pipeline for acute phase and prevention?. Expert Opinion on Investigational Drugs, 2022, , 1-23.	1.9	1
655	Platelet-to-Lymphocyte Ratio as Marker of Platelet Activation in Patients on Potent P2Y₁₂ Inhibitors. Journal of Cardiovascular Pharmacology and Therapeutics, 2022, 27, 107424842210965.	1.0	2
656	Antithrombotic agents: Platelet inhibitors, acute anticoagulants, fibrinolytics, and chronic anticoagulants. , 2013, , 332-397.		1

#	Article	IF	Citations
657	Impact of myocardial revascularization on long-term outcomes in a nationwide cohort of first acute myocardial infarction survivors. European Heart Journal Supplements, 2022, 24, C225-C232.	0.0	0
658	Polysaccharide-protein complex from coelomic fluid of Dendrobaena veneta earthworm exerts a multi-pathway antiplatelet effect without coagulopathy and cytotoxicity. Biomedicine and Pharmacotherapy, 2022, 151, 113205.	2.5	2
659	Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4. Journal of Medicinal Chemistry, 2022, 65, 8843-8854.	2.9	14
660	New oral protease-activated receptor 4 antagonist BMS-986120: tolerability, pharmacokinetics, pharmacodynamics, and gene variant effects in humans. Platelets, 2022, 33, 969-978.	1.1	7
661	Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials). American Journal of Cardiology, 2022, 178, 11-17.	0.7	3
662	Plasma levels of thrombin and activated protein C in patients with acute myocardial Infarction: An observational study. IJC Heart and Vasculature, 2022, 42, 101097.	0.6	0
663	Diversification of PAR signaling through receptor crosstalk. Cellular and Molecular Biology Letters, 2022, 27, .	2.7	5
664	A case history in natural product-based drug discovery: discovery of vorapaxar (Zontivityâ„¢). Medicinal Chemistry Research, 2022, 31, 1623-1636.	1.1	1
665	Emerging roles of protease-activated receptors in cardiometabolic disorders. Journal of Cardiology, 2023, 81, 337-346.	0.8	2
666	Biomarker-Based Prediction of RecurrentÂIschemic Events in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2022, 80, 1735-1747.	1.2	8
667	Novel approaches to antiplatelet therapy. Biochemical Pharmacology, 2022, 206, 115297.	2.0	4
668	Incidence of sudden cardiac arrest and sudden cardiac death after unstable angina pectoris and myocardial infarction. American Heart Journal, 2023, 257, 9-19.	1.2	8
669	Coronary thrombosis after European adder bite in a patient on dual antiplatelet therapy: A case report. Toxicon, 2022, 220, 106961.	0.8	2
670	Antiplatelet Therapy in Coronary Artery Disease: Now and Then. Seminars in Thrombosis and Hemostasis, 0, , .	1.5	2
671	Oligosaccharide Blocks PAR1 (Proteinase-Activated Receptor 1)-PAR4â€“Mediated Platelet Activation by Binding to Thrombin Exosite II and Impairs Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2023, 43, 253-266.	1.1	1
672	The Effect of Protease-Activated Receptor-1 (PAR-1) Inhibition on Endothelial-Related Biomarkers in Patients with Coronary Artery Disease. Thrombosis and Haemostasis, 2023, 123, 510-521.	1.8	2
673	Organocatalytic enantioselective construction of bicyclic Î³-butrolactones. Chinese Chemical Letters, 2023, 34, 108121.	4.8	0
674	Perspective: Collagen induced platelet activation via the GPVI receptor as a primary target of colchicine in cardiovascular disease. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	1

#	Article	IF	Citations
675	Organocatalytic Asymmetric Michael Addition Reaction of Aldehydes with 2-Furanones: Experimental, Applications and DFT Studies. Organic Chemistry Frontiers, 0, , .	2.3	0
676	Bleeding Risk With Antiplatelets and Bruton's Tyrosine Kinase Inhibitors in Patients With Percutaneous Coronary Intervention. , 2023, 2, 100608.		1
677	Antiplatelet Strategies Following PCI: A Review of Trials Informing Current and Future Therapies. , 2023, 2, 100607.		1
678	Efficacy, Safety, and Role of Antiplatelet Drugs in the Management of Acute Coronary Syndrome: A Comprehensive Review of Literature. Cureus, 2023, , .	0.2	2
679	Temporal trends in low-dose aspirin therapy for primary prevention of cardiovascular disease in European adults with and without diabetes. European Journal of Preventive Cardiology, 2023, 30, 1172-1181.	0.8	3
680	The Cellular Landscape of CTEPH Revealed by Single Cell Sequencing: Therapeutic Implications?. American Journal of Respiratory and Critical Care Medicine, 0, , .	2.5	1
681	Current concepts and novel targets for antiplatelet therapy. Nature Reviews Cardiology, 2023, 20, 583-599.	6.1	7